Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

• Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yannan J., Williams, Heather R., Brzezinska, Bogna N., Gaidis, Anna, Patel, Bhavi, Munroe, Janet, White, Joseph, Rungruang, Bunja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843391/
https://www.ncbi.nlm.nih.gov/pubmed/33537390
http://dx.doi.org/10.1016/j.gore.2021.100701
_version_ 1783644130740535296
author Wang, Yannan J.
Williams, Heather R.
Brzezinska, Bogna N.
Gaidis, Anna
Patel, Bhavi
Munroe, Janet
White, Joseph
Rungruang, Bunja
author_facet Wang, Yannan J.
Williams, Heather R.
Brzezinska, Bogna N.
Gaidis, Anna
Patel, Bhavi
Munroe, Janet
White, Joseph
Rungruang, Bunja
author_sort Wang, Yannan J.
collection PubMed
description • Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high solid tumors. • Targeting MSI-high ULMS with pembrolizumab can potentially maintain a patient’s quality of life and extend overall survival.
format Online
Article
Text
id pubmed-7843391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78433912021-02-02 Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature Wang, Yannan J. Williams, Heather R. Brzezinska, Bogna N. Gaidis, Anna Patel, Bhavi Munroe, Janet White, Joseph Rungruang, Bunja Gynecol Oncol Rep Case Report • Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high solid tumors. • Targeting MSI-high ULMS with pembrolizumab can potentially maintain a patient’s quality of life and extend overall survival. Elsevier 2021-01-13 /pmc/articles/PMC7843391/ /pubmed/33537390 http://dx.doi.org/10.1016/j.gore.2021.100701 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Wang, Yannan J.
Williams, Heather R.
Brzezinska, Bogna N.
Gaidis, Anna
Patel, Bhavi
Munroe, Janet
White, Joseph
Rungruang, Bunja
Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title_full Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title_fullStr Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title_full_unstemmed Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title_short Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
title_sort use of pembrolizumab in msi-high uterine leiomyosarcoma; a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843391/
https://www.ncbi.nlm.nih.gov/pubmed/33537390
http://dx.doi.org/10.1016/j.gore.2021.100701
work_keys_str_mv AT wangyannanj useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT williamsheatherr useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT brzezinskabognan useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT gaidisanna useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT patelbhavi useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT munroejanet useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT whitejoseph useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature
AT rungruangbunja useofpembrolizumabinmsihighuterineleiomyosarcomaacasereportandreviewoftheliterature

Ejemplares similares